Horizon Pharma Inc (HZNP) 18.35 $HZNP
Horizon Pharma plc Announces That Three of the Leading Proxy Advisory Firms Recommend That Depomed Shareholders Provide Consent FOR the Special Meetings Requests
Marketwired - Wed Oct 07, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Proxy Mosaic's ("Proxy Mosaic" recommendation in support of Horizon Pharma's efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. ("Depomed" directors and to repeal a series of recent amendments to Depomed's bylaws.
HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
3 Biotech Stocks That Have Been Unfairly Beaten Down
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Oct 06, 7:43AM CDT
Image by Gerald/Pixabay. What a brutal past few days it's been for biotech stocks. A simple tweet last week from presidential hopeful Hillary Clinton has caused biotech investors to get in a tizzy, and they've been selling off biotechs of all...
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
Horizon Pharma plc Announces Expansion and Relocation of U.S. Corporate Headquarters
Marketwired - Mon Oct 05, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it is expanding and relocating its U.S. corporate headquarters from Deerfield, Ill. to Lake Forest, Ill., with the signing of a long-term sublease for its new office space at 150 South Saunders Road.
HZNP: 18.35 (-0.56)
Horizon Pharma plc Announces Settlement of RAYOS(R) (prednisone) Delayed-Release Tablets Patent Litigation With Actavis Laboratories FL Inc.
Marketwired - Fri Oct 02, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliate Horizon Pharma Switzerland GmbH has entered into a settlement and license agreement with Actavis Laboratories FL, Inc. ("Actavis" to resolve pending patent litigation involving RAYOS(R) (prednisone) Delayed-Release Tablets.
HZNP: 18.35 (-0.56)
Jim Cramer's 'Mad Money' Recap: Here's the Silver Lining Behind the Dark Market Cloud
at The Street - Tue Sep 29, 7:30PM CDT
Stocks get cheaper as they head lower and every day we're inching closer to a bottom, Cramer says.
VRX: 169.83 (+3.83), TDOC: 16.23 (-0.41), AVP: 3.80 (+0.16), NKE: 122.10 (-1.09), CAG: 40.94 (-0.97), NUE: 40.58 (+0.66), XOM: 79.20 (+1.31), LLY: 83.99 (-0.18), HPQ: 28.01 (+0.01), XPO: 29.18 (+1.01), RAD: 6.17 (+0.08), TBI: 24.08 (+0.78), AGN: 268.99 (-3.89), AA: 10.94 (-0.04), ETP: 45.34 (+1.58), NVAX: 7.26 (+0.46), HZNP: 18.35 (-0.56), MCD: 101.77 (-0.13), ENB: 42.78 (+1.15), IEP: 76.05 (+1.52), X: 12.29 (+0.49), AAPL: 110.78 (-0.53), GIS: 55.72 (+0.02)
Hedge Funds Doing Battle Over Ailing Stocks
at The Street - Tue Sep 29, 10:47AM CDT
There's blood in the water.
AGN: 268.99 (-3.89), VRX: 169.83 (+3.83), ETP: 45.34 (+1.58), SUNE: 9.72 (+1.03), HZNP: 18.35 (-0.56), PAH: 12.94 (-1.48), WMB: 43.56 (+1.44), XPO: 29.18 (+1.01)
Horizon Pharma plc Announces Leading Proxy Advisory Service, Glass Lewis & Co., Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests
Marketwired - Tue Sep 29, 4:30AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma", a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Glass Lewis & Co. ("Glass Lewis", one of the nation's leading proxy advisory services, issued a report supporting Horizon Pharma's efforts to call for two related special meetings of Depomed, Inc. ("Depomed" shareholders -- one to remove all of the current Depomed directors and repeal a series of recent amendments to Depomed's bylaws (the "Removal and Bylaw Amendments Special Meeting" and a second to elect replacement directors (the "Election Special Meeting".
HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
The Biotechs Are Being Taken Out and Shot
at The Street - Tue Sep 29, 4:00AM CDT
All you can do is wait until they bottom out.
VRX: 169.83 (+3.83), HZNP: 18.35 (-0.56)
Institutional Shareholder Services (ISS) Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests
Marketwired - Mon Sep 28, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma", a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Institutional Shareholder Services' ("ISS" recommendation in support of Horizon Pharma's efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. ("Depomed" directors and to repeal a series of recent amendments to Depomed's bylaws.
HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
Depomed Issues Statement on ISS Report
PR Newswire - Mon Sep 28, 5:31AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company" today issued the following statement regarding a report by Institutional Shareholder Services' ("ISS" on Horizon Pharma plc's (NASDAQ: HZNP) ("Horizon" solicitation to call two special meetings of Depomed's shareholders (the "Special Meetings".
HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
EU panel says yes to key drugs
at Investor's Business Daily - Fri Sep 25, 5:47PM CDT
The European Union's medical advisory committee endorsed several key drugs, making EU approval likely for some potential blockbusters. The Committee for Medicinal Products for Human Use, known by its French acronym CHMP, adopted a positive opinion on...
VRTX: 109.40 (-0.06), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83)
Why Clinton Drug Cost Cap, R&D Mandate Hurt Valeant
at Investor's Business Daily - Fri Sep 25, 5:32PM CDT
Valeant Pharmaceuticals found plenty of company for its market misery last week as drugmakers and biotech stocks sold off after Hillary Clinton accused Big Pharma of price gouging. Valeant (VRX)closed nearly 18% lower for the week, and Biogen (BIIB),...
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), VRX: 169.83 (+3.83), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94)
5 Key Drugs That Just Won EU Endorsements
at Investor's Business Daily - Fri Sep 25, 2:19PM CDT
The European Union's medical advisory committee endorsed several key drugs from leading stocks Friday, making EU approval likely for some potential blockbusters: The Committee for Medicinal Products for Human Use, known by its French abbreviation,...
VRTX: 109.40 (-0.06), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83), XNCR: 12.49 (-0.17), CELG: 116.98 (+4.79)
Horizon Pharma plc Receives Positive CHMP Opinion for RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age
Marketwired - Fri Sep 25, 7:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, and its affiliate Horizon Therapeutics Limited today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion at its plenary monthly meeting in September recommending a centralized marketing authorization for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients greater than two months of age with Urea Cycle Disorders (UCDs). A full summary of the opinion can be found here. Detailed recommendations for the use of RAVICTI will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
HZNP: 18.35 (-0.56)
Can Valeant Heal After Clinton Price Gouging Tweet?
at Investor's Business Daily - Thu Sep 24, 10:37AM CDT
Valeant Pharmaceuticals (VRX) was among the specialty drug makers and biotech stocks that got clobbered this week after Hillary Clinton sent a tweet accusing Big Pharma of price gouging. In reaction to the Democratic front-runner's comments, Valeant...
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), VRX: 169.83 (+3.83), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94)
Horizon Pharma (HZNP) in Focus: Stock Plunges 12%
Zacks Equity Research - Zacks Investment Research - Wed Sep 23, 7:55AM CDT
Horizon Pharma's shares fell by nearly 12% on the day trading below the volatile price range of $27.37 to $31.92 in the past one-month time frame
GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
Market Wrap: Stocks Sink Across the Board
at The Street - Tue Sep 22, 3:59PM CDT
Materials and technology names led the way down on the session.
HRTX: 26.07 (+2.30), WFT: 10.43 (+0.02), HZNP: 18.35 (-0.56)
Stocks Pare Losses In Late Trade; Carnival Sinks, But Adobe Rallies
at Investor's Business Daily - Tue Sep 22, 3:25PM CDT
Stocks pared losses in the last hour of trade Tuesday to close off their session lows. The Dow Jones industrial average ended down 1.1%, the S&P 500 shed 1.2% and the Nasdaq fell 1.5%. Volume was mixed, running higher on the NYSE and lower on the...
AMSG: 81.41 (+2.16), VRX: 169.83 (+3.83), CCL: 49.25 (+0.09), HZNP: 18.35 (-0.56), ADBE: 80.65 (-4.50)
Hillary Keeps Pressuring Biotechs, But AutoZone Gets Earnings Lift
at Investor's Business Daily - Tue Sep 22, 1:58PM CDT
Stocks remained well underwater heading into the final hour of trading Tuesday as global growth concerns, falling commodity prices and Fed uncertainty continued to weigh. The Nasdaq slumped 1.9%, the S&P 500 1.6% and the Dow 1.4%. Volume was tracking...
VRX: 169.83 (+3.83), THO: 54.31 (+1.22), AZO: 736.00 (-8.62), FB: 92.40 (-0.40), HZNP: 18.35 (-0.56), SCMP: 19.25 (-0.12), ILMN: 145.94 (+0.13), AMGN: 148.05 (+6.83), ALK: 75.97 (+1.44), CELG: 116.98 (+4.79)
Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.08 (-0.01), GBSNU: 16.22 (-0.28), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AEZS: 0.09 (unch), WGBS: 1.52 (-0.12)
Horizon Pharma plc Announces That Three of the Leading Proxy Advisory Firms Recommend That Depomed Shareholders Provide Consent FOR the Special Meetings Requests
Marketwired - Wed Oct 07, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Proxy Mosaic's ("Proxy Mosaic" recommendation in support of Horizon Pharma's efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. ("Depomed" directors and to repeal a series of recent amendments to Depomed's bylaws. HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
3 Biotech Stocks That Have Been Unfairly Beaten Down
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Oct 06, 7:43AM CDT
Image by Gerald/Pixabay. What a brutal past few days it's been for biotech stocks. A simple tweet last week from presidential hopeful Hillary Clinton has caused biotech investors to get in a tizzy, and they've been selling off biotechs of all...
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
Horizon Pharma plc Announces Expansion and Relocation of U.S. Corporate Headquarters
Marketwired - Mon Oct 05, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it is expanding and relocating its U.S. corporate headquarters from Deerfield, Ill. to Lake Forest, Ill., with the signing of a long-term sublease for its new office space at 150 South Saunders Road.
HZNP: 18.35 (-0.56)
Horizon Pharma plc Announces Settlement of RAYOS(R) (prednisone) Delayed-Release Tablets Patent Litigation With Actavis Laboratories FL Inc.
Marketwired - Fri Oct 02, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliate Horizon Pharma Switzerland GmbH has entered into a settlement and license agreement with Actavis Laboratories FL, Inc. ("Actavis"
to resolve pending patent litigation involving RAYOS(R) (prednisone) Delayed-Release Tablets. HZNP: 18.35 (-0.56)
Jim Cramer's 'Mad Money' Recap: Here's the Silver Lining Behind the Dark Market Cloud
at The Street - Tue Sep 29, 7:30PM CDT
Stocks get cheaper as they head lower and every day we're inching closer to a bottom, Cramer says.
VRX: 169.83 (+3.83), TDOC: 16.23 (-0.41), AVP: 3.80 (+0.16), NKE: 122.10 (-1.09), CAG: 40.94 (-0.97), NUE: 40.58 (+0.66), XOM: 79.20 (+1.31), LLY: 83.99 (-0.18), HPQ: 28.01 (+0.01), XPO: 29.18 (+1.01), RAD: 6.17 (+0.08), TBI: 24.08 (+0.78), AGN: 268.99 (-3.89), AA: 10.94 (-0.04), ETP: 45.34 (+1.58), NVAX: 7.26 (+0.46), HZNP: 18.35 (-0.56), MCD: 101.77 (-0.13), ENB: 42.78 (+1.15), IEP: 76.05 (+1.52), X: 12.29 (+0.49), AAPL: 110.78 (-0.53), GIS: 55.72 (+0.02)
Hedge Funds Doing Battle Over Ailing Stocks
at The Street - Tue Sep 29, 10:47AM CDT
There's blood in the water.
AGN: 268.99 (-3.89), VRX: 169.83 (+3.83), ETP: 45.34 (+1.58), SUNE: 9.72 (+1.03), HZNP: 18.35 (-0.56), PAH: 12.94 (-1.48), WMB: 43.56 (+1.44), XPO: 29.18 (+1.01)
Horizon Pharma plc Announces Leading Proxy Advisory Service, Glass Lewis & Co., Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests
Marketwired - Tue Sep 29, 4:30AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Glass Lewis & Co. ("Glass Lewis", one of the nation's leading proxy advisory services, issued a report supporting Horizon Pharma's efforts to call for two related special meetings of Depomed, Inc. ("Depomed" shareholders -- one to remove all of the current Depomed directors and repeal a series of recent amendments to Depomed's bylaws (the "Removal and Bylaw Amendments Special Meeting" and a second to elect replacement directors (the "Election Special Meeting". HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
The Biotechs Are Being Taken Out and Shot
at The Street - Tue Sep 29, 4:00AM CDT
All you can do is wait until they bottom out.
VRX: 169.83 (+3.83), HZNP: 18.35 (-0.56)
Institutional Shareholder Services (ISS) Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests
Marketwired - Mon Sep 28, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today commented on Institutional Shareholder Services' ("ISS" recommendation in support of Horizon Pharma's efforts to call two related special meetings of Depomed shareholders to remove and replace all of the current Depomed, Inc. ("Depomed" directors and to repeal a series of recent amendments to Depomed's bylaws. HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
Depomed Issues Statement on ISS Report
PR Newswire - Mon Sep 28, 5:31AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
today issued the following statement regarding a report by Institutional Shareholder Services' ("ISS" on Horizon Pharma plc's (NASDAQ: HZNP) ("Horizon" solicitation to call two special meetings of Depomed's shareholders (the "Special Meetings". HZNP: 18.35 (-0.56), DEPO: 18.77 (+0.42)
EU panel says yes to key drugs
at Investor's Business Daily - Fri Sep 25, 5:47PM CDT
The European Union's medical advisory committee endorsed several key drugs, making EU approval likely for some potential blockbusters. The Committee for Medicinal Products for Human Use, known by its French acronym CHMP, adopted a positive opinion on...
VRTX: 109.40 (-0.06), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83)
Why Clinton Drug Cost Cap, R&D Mandate Hurt Valeant
at Investor's Business Daily - Fri Sep 25, 5:32PM CDT
Valeant Pharmaceuticals found plenty of company for its market misery last week as drugmakers and biotech stocks sold off after Hillary Clinton accused Big Pharma of price gouging. Valeant (VRX)closed nearly 18% lower for the week, and Biogen (BIIB),...
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), VRX: 169.83 (+3.83), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94)
5 Key Drugs That Just Won EU Endorsements
at Investor's Business Daily - Fri Sep 25, 2:19PM CDT
The European Union's medical advisory committee endorsed several key drugs from leading stocks Friday, making EU approval likely for some potential blockbusters: The Committee for Medicinal Products for Human Use, known by its French abbreviation,...
VRTX: 109.40 (-0.06), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83), XNCR: 12.49 (-0.17), CELG: 116.98 (+4.79)
Horizon Pharma plc Receives Positive CHMP Opinion for RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age
Marketwired - Fri Sep 25, 7:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, and its affiliate Horizon Therapeutics Limited today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion at its plenary monthly meeting in September recommending a centralized marketing authorization for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients greater than two months of age with Urea Cycle Disorders (UCDs). A full summary of the opinion can be found here. Detailed recommendations for the use of RAVICTI will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
HZNP: 18.35 (-0.56)
Can Valeant Heal After Clinton Price Gouging Tweet?
at Investor's Business Daily - Thu Sep 24, 10:37AM CDT
Valeant Pharmaceuticals (VRX) was among the specialty drug makers and biotech stocks that got clobbered this week after Hillary Clinton sent a tweet accusing Big Pharma of price gouging. In reaction to the Democratic front-runner's comments, Valeant...
AGN: 268.99 (-3.89), BIIB: 279.24 (+3.25), VRX: 169.83 (+3.83), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94)
Horizon Pharma (HZNP) in Focus: Stock Plunges 12%
Zacks Equity Research - Zacks Investment Research - Wed Sep 23, 7:55AM CDT
Horizon Pharma's shares fell by nearly 12% on the day trading below the volatile price range of $27.37 to $31.92 in the past one-month time frame
GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
Market Wrap: Stocks Sink Across the Board
at The Street - Tue Sep 22, 3:59PM CDT
Materials and technology names led the way down on the session.
HRTX: 26.07 (+2.30), WFT: 10.43 (+0.02), HZNP: 18.35 (-0.56)
Stocks Pare Losses In Late Trade; Carnival Sinks, But Adobe Rallies
at Investor's Business Daily - Tue Sep 22, 3:25PM CDT
Stocks pared losses in the last hour of trade Tuesday to close off their session lows. The Dow Jones industrial average ended down 1.1%, the S&P 500 shed 1.2% and the Nasdaq fell 1.5%. Volume was mixed, running higher on the NYSE and lower on the...
AMSG: 81.41 (+2.16), VRX: 169.83 (+3.83), CCL: 49.25 (+0.09), HZNP: 18.35 (-0.56), ADBE: 80.65 (-4.50)
Hillary Keeps Pressuring Biotechs, But AutoZone Gets Earnings Lift
at Investor's Business Daily - Tue Sep 22, 1:58PM CDT
Stocks remained well underwater heading into the final hour of trading Tuesday as global growth concerns, falling commodity prices and Fed uncertainty continued to weigh. The Nasdaq slumped 1.9%, the S&P 500 1.6% and the Dow 1.4%. Volume was tracking...
VRX: 169.83 (+3.83), THO: 54.31 (+1.22), AZO: 736.00 (-8.62), FB: 92.40 (-0.40), HZNP: 18.35 (-0.56), SCMP: 19.25 (-0.12), ILMN: 145.94 (+0.13), AMGN: 148.05 (+6.83), ALK: 75.97 (+1.44), CELG: 116.98 (+4.79)
Market Coverage on the Healthcare Sector -- AEterna Zentaris, Great Basin Scientific, Gilead Sciences, WaferGen Bio-systems and Horizon Pharma
PR Newswire - Tue Sep 22, 7:27AM CDT
ACI Association has initiated research coverage on the following equities: AEterna Zentaris Inc. (NASDAQ: AEZS), Great Basin Scientific, Inc. (NASDAQ: GBSN), Gilead Sciences, Inc. (NASDAQ: GILD), WaferGen Bio-systems, Inc. (NASDAQ: WGBS), Horizon Pharma plc (NASDAQ: HZNP). On Monday, September 21, 2015, Nasdaq ended at 4,828.95, up 0.04%, DOW advanced 0.77% to finish the day at 16,510.19, and the S&P closed at 1,966.97, up 0.46%. Register for your complimentary reports at the links given below.
GBSN: 0.08 (-0.01), GBSNU: 16.22 (-0.28), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56), AEZS: 0.09 (unch), WGBS: 1.52 (-0.12)
